论文部分内容阅读
我院自1989年12月至1995年12月用美国新泽西Kenilworth失灵葆雅公司生产的基因工程。a－2b型干扰素（IFN－γ）联COAP化疗方案治疗18例恶性淋巴瘤（ML）患者，并选择同期18例ML患者单用COAP化疗或加放疗作为对照组，现将治疗结果作一临床分析。临床资料一、一般资料治疗组18例
In our hospital, from December 1989 to December 1995, we used genetic engineering produced by the defective Nuova Company in Kenilworth, New Jersey, USA. Treatment of 18 patients with malignant lymphoma (ML) with a-2b interferon (IFN-γ) combined with COAP chemotherapy and 18 patients with ML in the same period were treated with COAP chemotherapy or radiotherapy alone as a control group. Clinical analysis. Clinical data I. General data treatment group 18 cases